Table 3 SABR planning and delivery variables (N = 42 patients)
Number of fiducials | 0 | N = 2 (5.0%)* |
1 | N = 8 (19.0%) | |
2 | N = 5 (12.0%) | |
3 | N = 21 (50.0%) | |
4 | N = 6 (14.0%) | |
Treatment duration (days) | 3 | N = 37 (88.1%) |
4 | N = 1 (2.4%) | |
5 | N = 3 (7.1%) | |
7 | N = 1 (2.4%) | |
PET scan data used for planning | Yes | N = 11 (26.0%) |
No | N = 31 (74.0%) | |
PTV size (cc) | Mean (95% CI) | 76.25 (63.83–88.67) |
Prescription dose (Gy) | Mean (95% CI) | 26.77 (19.33–113.39) |
Prescription Isodose (%) | Mean (95% CI) | 67.3 (65.24–69.35). |
Percentage Cover (%) | Mean (95% CI) | 96.6 (95.52–97.66) |
Min dose to PTV (Gy) | Mean (95% CI) | 22.29 (21.0–23.5) |
Max dose to PTV (Gy) | Mean (95% CI) | 40.2 (38.5–41.9) |
Mean dose to PTV (Gy) | Mean (95% CI) | 31.5 (30.8–32.3) |
Homogeneity Index (HI) | Mean (95% CI) | 1.5 (1.45–1.55) |
BED (Gy) | Mean (95% CI) | 50.3 (47.7–53.0) |
Fraction dose (Gy per fraction) | Mean (95% CI) | 8.9 (8.6–9.2) |
Delivery time (mins) | Mean (95% CI) | 71.4 (65.2–77.6) |